AHAnne Maria Hahn

Anne Maria Hahn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anne Maria Hahn has a total of 153 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Utilizing virus genomic surveillance to predict vaccine effectiveness

    by Jiye Kwon, Ke Li, Joshua L Warren, Sameer Pandya, Anne M Hahn, Yale SARS-CoV-2 Genomic Surveillance Initiative, Virginia E Pitzer, Daniel M Weinberger, Nathan D Grubaugh

    Background: Since the development of the first vaccines targeting the original SARS-CoV-2 virus sequence in 2020, mRNA-based vaccines have been updated three times: targeting Omicron BA.4/BA.5 in 2022, the XBB lineage in 2023, and the KP.2 variant in 2024. While genomic surveillance has advanced our understanding of pathogen diversity, gaps remain in incorporating genomic information to evaluate vaccine effectiveness (VE) against emerging variants. This study aims to characterize the relationship between VE and sequence-based genetic distance, to establish a framework for predicting near real-time changes in the level of vaccine protection from virus surveillance data. Methods: We analyzed 10,156 whole genome sequences of SARS-CoV-2 cases from Connecticut, USA, between April 2021 to July 2024. We first assessed how genetic distance, specifically the number of amino acid substitutions in the spike gene between COVID-19 case sequences and the mRNA vaccine formulation sequence(s), correlates with vaccine protection levels. Incorporating data from over 1 million test-negative controls, we developed a Bayesian time-varying model with autoregressive terms to assess VE at a weekly level. The analysis was adjusted for ZIP-code-level income, age, sex, and prior vaccine doses received. We then employed a random effects meta-regression to explore the relationship between VE and amino acid distance over time. Finally, we used the meta-regression model to estimate potential vaccine protection against emerging variants. Findings: We found that spike gene amino acid distance showed a negative correlation with VE over time. Stepwise increases in amino acid distance aligned with sharp VE declines during variant emergence, while accumulation of within-variant changes was also associated with gradual VE decline. Each 10 amino acid increase in distance in the spike gene corresponds to a predicted 15.4% (95% credible intervals (CrI): –2.0%, 34.6%) reduction in VE. For the 2023/24 updated vaccine, spike distance rose from 12.25 to 30.23, predicting a 43.4% (95% CrI: –5.7%, 90.1%) drop in VE using sequence information alone. Conclusion: Our framework quantifies how the emergence of new variants is expected to affect VE for SARS-CoV-2. By quantifying the relationship between amino acid substitutions and time-varying VE, we leverage intrinsic pathogen features, such as spike amino acid distance, to inform future vaccine updates using genomic sequences. As genomic surveillance data becomes more widely available across pathogens, this framework can serve as a near-real time surveillance tool to infer population-level protection and offers valuable insights for vaccine update decisions.


  • Open Access

    Editorial: IUIS junior community: pushing the frontiers of immunology

    by Adeleye O. Adeshakin, Anne M. Hahn

    Cruz-Cárdenas et al. report the generation of CRISPR/Cas9-engineered neutrophil-like cell lines lacking either CD16b or CD32a, overcoming a major barrier to dissecting receptor-specific FcγR signaling, cytokine regulation, and ROS generation in neutrophils. By establishing CD16b -/-and CD32a -/-promyelocytic lines that differentiate into neutrophil-like cells, they provide a donor-independent platform to interrogate FcγR function, revealing distinct cytokine signatures and offering a powerful genetic system for mechanistic immunology and therapeutic Fc engineering (1).Information System® /monoclonal Antibodies (IMGT/mAb)-Knowledge Graph (IMGT/mAb-KG), a structured, interoperable graph that integrates therapeutic monoclonal antibody data with IMGT genomic and structural resources (2). This resource, comprising over 100,000 triples and covering nearly 1,500 mAbs, hundreds of targets and indications, and about 40,000 of study products. It enables sophisticated, cross-cutting queries on constructs, clinical development, mechanisms of action, and paratope-epitope relationships, thereby providing a robust informatics substrate for computational immunology and mAb discovery workflows.Mentuci et al. present a comprehensive review of how cancer-associated fibroblasts (CAFs) impair dendritic cell (DC) biology across solid tumors, framing CAF-DC crosstalk as a key stromal axis of immune escape and a promising target for next-generation immunotherapy. By integrating DC subset biology with tumor microenvironment remodeling, they show how CAF-driven DC dysfunction skews adaptive immunity toward tolerance and regulatory phenotypes (3). They further proposed that effective restoration of DC function will require combined DC-targeted strategies and stromal/CAF reprogramming to improve responses to vaccines, checkpoint blockade, and radiotherapy. Ruffinatto et al. review evidence positioning hematopoietic stem cells (HSCs) as a central reservoir of innate immune memory, emphasizing early hematopoiesis with myeloid bias as a key determinant of long-term innate responses to infectious and inflammatory challenges (4). By synthesizing data on how cytokines, Pathogen-Associated Molecular Patterns (PAMPs), pathogens, and vaccines imprint HSCs, they link specific inflammatory environment to durable changes in lineage bias, function, and HSC exhaustion. Thus, propose that targeted modulation of "HSC training" could be exploited to enhance protective trained immunity or to mitigate maladaptive inflammatory memory in chronic disease and transplantation contexts (5).China to identify differences in infections with or without vaccination via regression modelling. They found that breakthrough infections were more likely to occur after receiving one vaccine dose and in the youngest age group. Their findings highlight the reduction of vaccine breakthrough cases in recipients of two vaccine doses in line with the World Health organization's recently updated recommendations (6). They also point out the need to explore potential benefits of further booster vaccinations. Mechanistic insights into such questions could benefit from serological and laboratory analysis to further improve our understanding on how vaccination shapes disease transmission dynamics (7).Taken together, this first IUIS Junior Community Research Topic showcases impactful advances by early-career immunologists in cellular engineering, immunoinformatics, tumor immunology, stem cellbased innate immune memory and epidemiology, while acknowledging that many additional breakthroughs from junior investigators remain to be captured. Building on this momentum, submissions are now welcomed for "IUIS Junior Community: Research Topic -Volume II," which aims to further amplify the scientific voice and visibility of the next generation of immunologists. While our IUIS Junior Community continues to grow, we hope for even more geographical and topical diversity for the next submissions and continue highlighting the excellent work that is done by immunologists around the world.

  • Open Access

    Integrated Analysis of the 2022 SARS-CoV-2 Omicron Lineage Replacement Dynamics in Connecticut, US

    by Nicholas F. G. Chen, Kien Pham, Chrispin Chaguza, Rafael Lopes, Fayette Klaassen, Chaney C. Kalinich, Yale SARS-CoV-2 Genomic Surveillance Initiative, Nicholas Kerantzas, Sameer Pandya, David Ferguson, et al.

    In 2022, consecutive sweeps of highly transmissible SARS-CoV-2 Omicron-derived lineages (B.1.1.529*) maintained viral transmission despite extensive antigen exposure from both vaccinations and infections. To better understand Omicron variant emergence in the context of the dynamic fitness landscape of 2022, we aimed to explore putative drivers behind SARS-CoV-2 lineage replacements. Variant fitness is determined through its ability to either outrun previously dominant lineages or more efficiently circumvent host immune responses to previous infections and vaccinations. By analyzing data collected through our local genomic surveillance program from Connecticut, USA, we compared emerging Omicron lineages’ growth rates, estimated infections, effective reproductive rates, average viral copy numbers, and likelihood for causing infections in recently vaccinated individuals. We find that newly emerging Omicron lineages outcompeted dominant lineages through a combination of enhanced viral shedding or advanced immune escape depending on the population-level exposure state. This analysis integrates individual-level sequencing data with demographic, vaccination, laboratory, and epidemiological data and provides further insights into host–pathogen dynamics beyond public aggregate data.


  • Open Access

    Genome-wide association study between SARS-CoV-2 single nucleotide polymorphisms and virus copies during infections

    by Ke Li, Chrispin Chaguza, Julian Stamp, Yi Ting Chew, Nicholas F. G. Chen, David Ferguson, Sameer Pandya, Nick Kerantzas, Wade Schulz, Yale SARS-CoV-2 Genomic Surveillance Initiative, et al.

    Significant variations have been observed in viral copies generated during SARS-CoV-2 infections. However, the factors that impact viral copies and infection dynamics are not fully understood, and may be inherently dependent upon different viral and host factors. Here, we conducted virus whole genome sequencing and measured viral copies using RT-qPCR from 9,902 SARS-CoV-2 infections over a 2-year period to examine the impact of virus genetic variation on changes in viral copies adjusted for host age and vaccination status. Using a genome-wide association study (GWAS) approach, we identified multiple single-nucleotide polymorphisms (SNPs) corresponding to amino acid changes in the SARS-CoV-2 genome associated with variations in viral copies. We further applied a marginal epistasis test to detect interactions among SNPs and identified multiple pairs of substitutions located in the spike gene that have non-linear effects on viral copies. We also analyzed the temporal patterns and found that SNPs associated with increased viral copies were predominantly observed in Delta and Omicron BA.2/BA.4/BA.5/XBB infections, whereas those associated with decreased viral copies were only observed in infections with Omicron BA.1 variants. Our work showcases how GWAS can be a useful tool for probing phenotypes related to SNPs in viral genomes that are worth further exploration. We argue that this approach can be used more broadly across pathogens to characterize emerging variants and monitor therapeutic interventions.


  • SARS-CoV-2-related bat viruses evade human intrinsic immunity but lack efficient transmission capacity

    by Mario A. Peña-Hernández, Mia Madel Alfajaro, Renata B. Filler, Miyu Moriyama, Emma L. Keeler, Zara E. Ranglin, Yong Kong, Tianyang Mao, Bridget L. Menasche, Madeleine C. Mankowski, et al.

    Circulating bat coronaviruses represent a pandemic threat. However, our understanding of bat coronavirus pathogenesis and transmission potential is limited by the lack of phenotypically characterized strains. We created molecular clones for the two closest known relatives of SARS-CoV-2, BANAL-52 and BANAL-236. We demonstrated that BANAL-CoVs and SARS-CoV-2 have similar replication kinetics in human bronchial epithelial cells. However, BANAL-CoVs have impaired replication in human nasal epithelial cells and in the upper airway of mice. We also observed reduced pathogenesis in mice and diminished transmission in hamsters. Further, we observed that diverse bat coronaviruses evade interferon and downregulate major histocompatibility complex class I. Collectively, our study demonstrates that despite high genetic similarity across bat coronaviruses, prediction of pandemic potential of a virus necessitates functional characterization. Finally, the restriction of bat coronavirus replication in the upper airway highlights that transmission potential and innate immune restriction can be uncoupled in this high-risk family of emerging viruses.


  • Open Access

    Escalating combinations of enhanced infectivity and immune escape define SARS-CoV-2 Omicron lineage replacement

    by Nicholas F.G. Chen, Kien Pham, Chrispin Chaguza, Rafael Lopes, Fayette Klaassen, Daniel M. Weinberger, Virginia E. Pitzer, Joshua L. Warren, Nathan D. Grubaugh, Anne M. Hahn

    In 2022, consecutive sweeps of the highly transmissible SARS-CoV-2 Omicron-family maintained high viral transmission levels despite extensive antigen exposure on the population level resulting from both vaccinations and infections. To better understand variant fitness in the context of the highly dynamic immunity landscape of 2022, we aimed to dissect the interplay between immunity and fitness advantages of emerging SARS-CoV-2 Omicron lineages on the population-level. We evaluated the relative contribution of higher intrinsic transmissibility or immune escape on the fitness of emerging lineages by analyzing data collected through our local genomic surveillance program from Connecticut, USA. We compared growth rates, estimated infections, effective reproductive rates, average viral copy numbers, and likelihood for causing vaccine break-through infections. Using these population-level data, we find that newly emerging Omicron lineages reach dominance through a specific combination of enhanced intrinsic transmissibility and immune escape that varies over time depending on the state of the host-population. Using similar frameworks that integrate whole genome sequencing together with clinical, laboratory, and epidemiological data can advance our knowledge on host-pathogen dynamics in the post-emergence phase that can be applied to other communicable diseases beyond SARS-CoV-2.

  • Open Access

    Combining genomic data and infection estimates to characterize the complex dynamics of SARS-CoV-2 Omicron variants in the United States

    by Rafael Lopes, Kien Pham, Fayette Klaassen, Melanie H. Chitwood, Anne M. Hahn, Seth Redmond, Nicole A. Swartwood, Joshua A. Salomon, Nicolas A. Menzies, Ted Cohen, et al.

    SARS-CoV-2 Omicron surged as a variant of concern in late 2021. Subsequently, several distinct Omicron variants have appeared and overtaken each other. We combined variant frequencies and infection estimates from a nowcasting model for each US state to estimate variant-specific infections, attack rates, and effective reproduction numbers (R t ). BA.1 rapidly emerged, and we estimate that it infected 47.7% of the US population between late 2021 and early 2022 before it was replaced by BA.2. We estimate that BA.5, despite a slower takeoff than BA.1, infected 35.7% of the US population, persisting in circulation for nearly 6 months. Other Omicron variants - BA.2, BA.4, and XBB - together infected 30.7% of the US population. We found a positive correlation between the state-level BA.1 attack rate and social vulnerability and a negative correlation between the BA.1 and BA.2 attack rates. Our findings illustrate the complex interplay between viral evolution, population susceptibility, and social factors during the Omicron emergence in the US.


  • Open Access

    Survey of white-footed mice in Connecticut, USA reveals low SARS-CoV-2 seroprevalence and infection with divergent betacoronaviruses

    by Rebecca Earnest, Anne M. Hahn, Nicole M. Feriancek, Matthew Brandt, Renata B. Filler, Zhe Zhao, Mallery I. Breban, Chantal B.F. Vogels, Nicholas F.G. Chen, Robert T. Koch, et al.

    Diverse mammalian species display susceptibility to and infection with SARS-CoV-2. Potential SARS-CoV-2 spillback into rodents is understudied despite their host role for numerous zoonoses and human proximity. We assessed exposure and infection among white-footed mice ( Peromyscus leucopus ) in Connecticut, USA. We observed 1% (6/540) wild-type neutralizing antibody seroprevalence among 2020-2022 residential mice with no cross-neutralization of variants. We detected no SARS-CoV-2 infections via RT-qPCR, but identified non-SARS-CoV-2 betacoronavirus infections via pan-coronavirus PCR among 1% (5/468) of residential mice. Sequencing revealed two divergent betacoronaviruses, preliminarily named Peromyscus coronavirus-1 and -2 . Both belong to the Betacoronavirus 1 species and are ∼90% identical to the closest known relative, Porcine hemagglutinating encephalomyelitis virus . Low SARS-CoV-2 seroprevalence suggests white-footed mice may not be sufficiently susceptible or exposed to SARS-CoV-2 to present a long-term human health risk. However, the discovery of divergent, non-SARS-CoV-2 betacoronaviruses expands the diversity of known rodent coronaviruses and further investigation is required to understand their transmission extent.


  • Open Access

    High-fat-diet-associated intestinal microbiota exacerbates psoriasis-like inflammation by enhancing systemic γδ T cell IL-17 production

    by Koshiro Sonomoto, Rui Song, Daniel Eriksson, Anne M. Hahn, Xianyi Meng, Pang Lyu, Shan Cao, Ning Liu, R. Verena Taudte, Stefan Wirtz, et al.


  • Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose

    by Bruno Andraus Filardi, Valter Silva Monteiro, Pedro Vellosa Schwartzmann, Vivian Do Prado Martins, Luis Eduardo Rosa Zucca, Gabriela Crispim Baiocchi, Amyn A. Malik, Julio Silva, Anne M. Hahn, Nicholas F. G. Chen, et al.

    The emergence of the SARS-CoV-2 Omicron sublineages resulted in increased transmission rates and reduced protection from vaccines. To counteract these effects, multiple booster strategies were used in different countries, although data comparing their efficiency in improving protective immunity remain sparse, especially among vulnerable populations, including older adults. The inactivated CoronaVac vaccine was among the most widely distributed vaccine worldwide and was essential in the early control of SARS-CoV-2–related hospitalizations and deaths. However, it is not well understood whether homologous versus heterologous booster doses in those fully vaccinated with CoronaVac induce distinct humoral responses or whether these responses vary across age groups. We analyzed plasma antibody responses from CoronaVac-vaccinated younger or older individuals who received a homologous CoronaVac or heterologous BNT162b2 or ChAdOx1 booster vaccine. All three evaluated boosters resulted in increased virus-specific IgG titers 28 days after the booster dose. However, we found that both IgG titers against SARS-CoV-2 Spike or RBD and neutralization titers against Omicron sublineages were substantially reduced in participants who received homologous CoronaVac compared with the heterologous BNT162b2 or ChAdOx1 booster. This effect was specifically prominent in recipients >50 years of age. In this group, the CoronaVac booster induced low virus-specific IgG titers and failed to elevate neutralization titers against any Omicron sublineage. Our results point to the notable inefficiency of CoronaVac immunization and boosting in mounting protective antiviral humoral immunity, particularly among older adults, during the Omicron wave. These observations also point to benefits of heterologous regimens in high-risk populations fully vaccinated with CoronaVac.